GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Short-Term Debt

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Short-Term Debt : $0.08 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Short-Term Debt?

Paradigm Biopharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.08 Mil.

Paradigm Biopharmaceuticals's quarterly Short-Term Debt declined from Dec. 2022 ($0.07 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.08 Mil).


Paradigm Biopharmaceuticals Short-Term Debt Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Short-Term Debt Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 - 0.07 - 0.08

Paradigm Biopharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Paradigm Biopharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Headlines

From GuruFocus